several neutralizing antibodies (Supplementary Methods) , and found that the 6 9 modelling results support the interactions between 2019-nCoV RBD and certain 7 0 SARS-CoV antibodies (Figure 1b ). This could be due to the relatively high identity 7 1 (73%) of RBD in 2019-nCoV and SARS-CoV (Figure 1c ). For instance, residues in 7 2 RBD of SARS-CoV that make polar interactions with a neutralizing antibody m396 as 7 3 indicated by the complex crystal structure [10] are invariably conserved in 7 4 2019-nCoV RBD (Figure 1d ). In the structure of SARS-CoV-RBD-m396, R395 in 7 5 RBD formed a salt bridge with D95 of m396-VL. Concordantly, the electrostatic 7 6
interaction was also observed in the model of 2019-nCoV-RBD-m396, forming by 7 7 R408 (RBD) and D95 (m396-VL). This analysis suggests that some 7 8 SARS-CoV-specific monoclonal antibodies may be effective in neutralizing 7 9 2019-nCoV. In contrast, the interactions between antibody F26G19 [11] or 80R [12] 8 0 and the RBD in 2019-nCoV decreased significantly due to the lack of salt bridges 8 1 formed by R426-D56 in SARS-CoV-RBD-F26G19 or D480-R162 in 8 2 SARS-CoV-RBD-80R, respectively. Furthermore, while most of the 80R-binding 8 3 residues on the RBD of SARS-CoV are not conserved on RBD of 2019-nCoV ( Figure  8  4 1c), it is unlikely that the antibody 80R could effectively recognize 2019-nCoV. 8 5 Therefore, it is urgent to experimentally determine the cross-reactivity of 8 6 anti-SARS-CoV antibodies with 2019-nCoV spike protein, which could have 8 7 important implications for rapid development of vaccines and therapeutic antibodies 8 8 against 2019-nCoV. 8 9
In this study, we first expressed and purified 2019-nCoV RBD protein 9 0 (Supplementary Methods). We also predicted the conformations of 2019-nCoV RBD 9 1 and its complex with the putative receptor, human ACE2 (Supplementary Methods). 9 2
Comparison of the interaction between complex of ACE2 [13] and SARS-CoV RBD 9 3 and homology model of ACE2 and 2019-nCoV RBD revealed similar binding modes 9 4 (data not shown). In both complexes, β 5-β6 loop and β 6-β7 loop form extensive 9 5 contact, including at least seven pairs of hydrogen bonds, with the receptor. Notably, 9 6 R426 on the forth α helix in SARS-CoV RBD builds a salt bridge with E329 and a 9 7 hydrogen bond with Q325 on ACE2. However, the arginine (R426 in SARS-CoV 9 8 RBD) to asparagine (N439) mutation in 2019-nCoV RBD abolished the strong polar 9 9
interactions, which may induce a decrease in the binding affinity between RBD and Indeed, we measured the binding of 2019-nCoV RBD to human ACE2 by the biolayer 1 0 5 interferometry binding (BLI) assay, and found that 2019-nCoV RBD bound potently 1 0 6 to ACE2. The calculated affinity (K D ) of 2019-nCoV RBD with human ACE2 was 1 0 7 15.2 nM (Figure 1f ), which is comparable to that of SARS-CoV spike protein with 1 0 8 human ACE2 (15 nM) [14] . These results indicate that ACE2 could be the potential 1 0 9 receptor for the new coronavirus, and that the expressed 2019-nCoV RBD protein is ( Supplementary Methods, Figure 1e) . Surprisingly, we found that most of these 1 1 7
antibodies did not show evident binding to 2019-nCoV RBD. To confirm this result, 1 1 8 we further measured the binding kinetics using BLI (Supplementary Methods). An 1 1 9 irrelevant anti-CD40 antibody was used as negative control. Similarly, the antibody 1 2 0 m396, which was predicted to bind 2019-nCoV RBD (Figure 1d ), only showed slight 1 2 1 binding at the highest measured concentration (2 µM). Interestingly, we found that 1 2 2 there are several additional asparagine residues in 2019-nCoV RBD as compared with 1 2 3 SARS-CoV RBD. For instance, the N439 residue is located in the receptor binding 1 2 4 site within 2019-nCoV RBD. It could be hypothesized that Asn-linked glycosylation 1 2 5 may occur, rendering the computationally simulated models far from the native 1 2 6 structures. Further studies are needed to solve the high-resolution structure of 1 2 7 2019-nCoV RBD and understand why it could not be recognized by these antibodies. 1 2 8
Notably, one SARS-CoV-specific antibody, CR3022, was found to bind potently 1 2 9
with 2019-nCoV RBD as determined by ELISA and BLI (Figure 1e, 1f ). It followed a 1 3 0 fast-on (k on of 1.84×10 5 Ms -1 ) and slow-off (k off of 1.16×10 -3 s -1 ) binding kinetics, 1 3 1 resulting in a K D of 6.3 nM (Figure 1f ). This antibody was isolated from blood of a 1 3 2 convalescent SARS patient, and did not compete with the antibody CR3014 for 1 3 3 binding to recombinant S protein [5] . To further elucidate the binding epitopes of 1 3 4 CR3022, we measured the competition of CR3022 and human ACE2 for the binding 1 3 5 to 2019-nCoV RBD (Supplementary Methods). The streptavidin biosensors labelled 1 3 6 with biotinylated 2019-nCoV RBD were saturated with human ACE2 in solution, 1 3 7
followed by the addition of the test antibodies in the presence of ACE2. As shown in 1 3 8 Figure 1g , the antibody CR3022 did not show any competition with ACE2 for the 1 3 9 binding to 2019-nCoV RBD. These results suggest that CR3022, distinct from the 1 4 0 other two SARS-CoV antibodies, recognizes an epitope that does not overlap with the 1 4 1 ACE2 binding site of 2019-nCoV RBD. 1 4 2
The RBD of 2019-nCoV differ largely from the SARS-CoV at the C-terminus 1 4 3 residues (Figure 1c ). Our results implied that such difference did not result in drastic 1 4 4 changes in the capability to engage the ACE2 receptor, but had a critical impact for 1 4 5 the cross-reactivity of neutralizing antibodies. Some of the most potent 1 4 6 SARS-CoV-specific neutralizing antibodies (e.g., m396, CR3014) that target the 1 4 7 receptor binding site of SARS-CoV failed to bind 2019-nCoV spike protein, 1 4 8 indicating that it is necessary to develop novel monoclonal antibodies that could bind 1 4 9 specifically to 2019-nCoV RBD. Interestingly, it was reported that the antibody 1 5 0 CR3022 could neutralize the antibody CR3014 escape viruses, and that no escape 1 5 1 variants could be generated with CR3022 [5] . Furthermore, the mixture of CR3022 1 5 2 and CR3014 neutralized SARS-CoV in a synergistic fashion by recognizing different 1 5 3 epitopes on RBD [5] . Therefore, CR3022 has the potential to be developed as 1 5 4 candidate therapeutics, alone or in combination with other neutralizing antibodies, for 1 5 5
